TAK 003

Drug Profile

TAK 003

Alternative Names: Dengue vaccine tetravalent - Takeda Pharmaceuticals; DENVax™ - Takeda Pharmaceuticals; Needle-free dengue vaccine; TAK 003; Tetravalent dengue vaccine - Takeda Pharmaceuticals

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Centers for Disease Control and Prevention; Inviragen
  • Developer PharmaJet; Takeda Pharmaceuticals USA
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Dengue

Most Recent Events

  • 08 Nov 2016 Takeda plans a phase II trial for Dengue (In volunteers, In children) in Philippines and Manila (NCT02948829)
  • 01 Apr 2016 Inviragen completes a phase II trial in Dengue (Prevention, In children, In adolescents, In adults) in Puerto Rico, Colombia, Singapore, and Thailand (NCT01511250 )
  • 01 Apr 2016 Phase-III clinical trials in Dengue (In adolescents, In children, Prevention) in Panama (SC) (NCT02747927)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top